ORTHO MICRONOR also known as the mini-pill, is a "progestin-only" pill. Unlike conventional birth control pills ("combination pills"), ORTHO MICRONOR contains no estrogen and a lower level of progestin than conventional birth control pills. Click here for prescribing information: http://www.orthomicronor.com/products/pi/pdfs/micro.pdf#zoom=100

Although access to this page is not restricted, the information found here is intended for use by medical providers. Patients should address specific medical concerns with their physicians. Please see the Terms and Conditions. This page was written by Scott Moses, MD, and was last revised 1/24/2007. Please send comments and questions to the editor. Contact information may be found on the page About the Family Practice Notebook. © 2000, Family Practice Notebook, LLC . These pages are best viewed with Microsoft Internet Explorer 5.0 or greater for full functionality.

ZOMIG should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease. ZOMIG should not be administered to patients with hemiplegic or basilar migraine.

© 2007 Lippincott Williams & Wilkins, Inc. Volume 25(9), October 2007, p 602–607

Am J Health-Syst Pharm. 2006;63(23):2354-2356. ©2006 American Society of Health-System Pharmacists. Posted 01/17/2007. Conclusion: A patient's INR values increased after the addition of prednisone to his warfarin regimen. Registration Required.

WebMd Health

WebMD Health

Last Revised - 10/01/2006

RELPAX Tablets should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms, or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease. RELPAX Tablets should not be given to patients with cerebrovascular syndromes including (but not limited to) strokes of any type as well as transient ischemic attacks. RELPAX Tablets should not be given to patients with peripheral vascular disease including (but not limited to) ischemic bowel disease. RELPAX Tablets should not be administered to patients with hemiplegic or basilar migraine.

Sumatriptan succinate tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptan succinate tablets. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease. Sumatriptan succinate tablets should not be administered to patients with hemiplegic or basilar migraine.

Last Revised - 04/01/2003

While the safety of the morning-after pill has not been studied in women who have a prior history of blood clots or have a known clotting disorder, such as factor V Leiden or protein S deficiency, the pill likely does not predispose to a significant excess risk in these individuals, since (a) the treatment is very short and (b) any potential risk is likely less than the thrombotic risk associated with the pregnancy that treatment is being offered to prevent.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: aspirin-sensitive asthma (a history of worsening breathing with runny/stuffy nose after taking aspirin or other NSAIDs), heart disease (such as chest pain, previous heart attack), decreased blood flow in the brain (such as previous stroke, transient ischemic attack), blood circulation disease (such as ischemic bowel disease, Raynaud's disease), certain types of headaches (hemiplegic or basilar migraine), liver disease, previous or planned heart bypass surgery (CABG).

A nonsteroidal anti-inflammatory drug commonly given to people taking blood thinners since it has the least interaction with Coumadin of all anti-inflammatories.

AMERGE Tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive AMERGE Tablets. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e. g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal's variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease. AMERGE Tablets should not be administered to patients with hemiplegic or basilar migraine.

CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 73 • NUMBER 3 MARCH 2006. SYNOPSIS OF THE STUDY Conventional wisdom has been that oral contraceptives should not be given to women with SLE because of theoretical concerns that estrogens play a role in disease activity. In this study, the authors identified 183 women younger than 40 years (younger than 36 years if smokers) with stable or improving disease. Exclusion criteria included hypertension, a history of thromboembolic disease, anticardiolipin antibodies, lupus anticoagulant, gynecologic cancer, a history of myocardial infarction, migraines, or liver disease. Study patients were randomly assigned (allocation concealed) to triphasic ethinyl estradiol plus norethindrone (Ortho-Novum 7/7/7) or matching placebo and followed up for 1 year. Slightly more than one third in each group discontinued the study medication; analysis was by intention to treat, though, which is appropriate. During follow-up there was no difference in the frequency of flares (7.6% vs 7.7%) and no difference between groups regarding a disease-specific symptom score. There was also no difference between groups in the number of thromboembolic events.

CONTRAINDICATIONS: Cardiac, Cerebrovascular, or Peripheral Vascular Disease: TREXIMET should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive TREXIMET, nor should patients who have had coronary artery bypass graft (CABG) surgery. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina, such as the Prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease.

Posted Fri, Aug 31, 2007, 1:25 am PDT. © 2007 Johns Hopkins University

MAXALT should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease. MAXALT should not be administered to patients with hemiplegic or basilar migraine.